Status:

COMPLETED

Treatment of Patients With Idiopathic Membranous Nephropathy

Lead Sponsor:

Radboud University Medical Center

Conditions:

Glomerulonephritis, Membranous

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

Patients with idiopathic membranous nephropathy at risk for renal failure can be identified in an early stage by measuring urinary low molecular weight proteins and urinary immunoglobulin G (IgG). Thi...

Detailed Description

Inclusion Criteria: * patients with idiopathic membranous nephropathy * nephrotic syndrome * normal renal function (serum creatinine \[Screat\] \< 1.5 mg/dl) * elevated urinary beta2-microglobulin an...

Eligibility Criteria

Inclusion

  • Idiopathic membranous nephropathy
  • Serum creatinine \< 1.5 mg/dl
  • Nephrotic syndrome

Exclusion

  • Infection
  • Instable angina
  • Systemic disease
  • Pregnancy
  • Renal vein thrombosis
  • Prior therapy with immunosuppressant agents
  • Liver dysfunction
  • Use of nonsteroidal anti-inflammatory drugs (NSAIDs)

Key Trial Info

Start Date :

July 1 1997

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2008

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT00135954

Start Date

July 1 1997

End Date

July 1 2008

Last Update

January 28 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Nephrology Radboud University Nijmegen Medical Centre

Nijmegen, Netherlands, 6500 HB